StageZero Life Sciences Announces Delay in Q4 and Year End 2023 Financial Results

StageZero Life Sciences Ltd., a healthcare company noted for its novel mRNA multi-cancer diagnostic tool, Aristotle, and its oncologist-led treatment protocol, disclosed a delay in filing their end-of-year financial statements for 2023. The Toronto-based firm was unable to meet the April 2, 2024 deadline for its audited consolidated financial statements, management discussion, and analysis, along with management certifications of annual filings set by Canadian securities laws. StageZero anticipates filing its Annual Report on Form 20-F within the U.S. filing deadline, with a commitment to releasing its financial outcomes for Q4 and the entire year of 2023 by May 31, 2024.

The delay is attributed to the company's financial constraints that prevented full payment to their auditor for completing the annual audit. Interaction with the Ontario Securities Commission has resulted in StageZero applying for a Management Cease Trade Order, pending the overdue filings. This step aims to keep the market informed through bi-weekly updates until the official release of the financial reports. Despite the setback, StageZero is optimistic about its Q4 2023 revenue aligning with previous quarters of 2023 and confirms no insolvency proceedings or undisclosed material information at this time.